Friday, June 5, 2026
RSS

Inside BCI

Brain-Computer Interface Industry News
Industry News Research Policy Opinion Market Moves
About Directory Glossary

Tag: market

14 articles

Market Moves

Allen Institute launches $400M Brain Health accelerator with Bezos family and AWS, naming ALS as one of five focus diseases

The Allen Institute announced on 2 June 2026 a $400 million global research initiative called the Brain Health accelerator, targeting neurodegenerative disease at the cell and circuit level. Capital is $200 million from the Allen Institute, $100 million from the Bezos family (whose Bezos Expeditions arm backs Synchron), and $100 million combined from AWS, NIH, and ALS advocacy organisation EverythingALS. The ALS focus is the most direct adjacency to the implantable BCI cohort, which has anchored most of its early commercial work on ALS patients.

Jun 5

Market Moves

Australian brain-mapping company Omniscient closes $27.2M Series D, naming brain-computer interfaces as a target expansion market

Sydney and San Francisco-based Omniscient Neurotechnology closed a $27.2 million (AU$41.1 million) Series D funding round on 29 May 2026, co-led by OIF Ventures and the Australian National Reconstruction Fund Corporation. The capital scales the company's FDA-cleared Quicktome connectomics platform for neurosurgical planning, with the company explicitly naming brain-computer interface, stroke, and movement disorders as the next expansion indications. Omniscient is a connectomics company rather than a BCI implant company; the BCI angle is forward-looking adjacency rather than current product.

May 29

Market Moves

Tencent takes a minority stake in Hangzhou brain-chip developer Nanochap Electronics

Tencent Holdings has acquired a minority equity stake in Nanochap Electronics, a Hangzhou-based fabless semiconductor company specialising in neural interface and biosensing SoCs for brain-computer interface and medical device applications. The investment was disclosed through a 28 May 2026 business registration filing showing Shanghai Qishan Investment, a Tencent subsidiary, added as a new shareholder. Nanochap's registered capital increased to RMB 16.8853 million. Exact stake size and investment amount have not been publicly disclosed. The move follows the April 2026 StairMed funding round in which Alibaba led and Tencent joined, and signals a sustained pattern of Chinese big-tech equity participation in the country's BCI silicon supply chain.

May 29

Market Moves

ONWARD Medical posts EUR 2M Q1 revenue, advances ARC-BCI to seven implanted participants, begins Empower BP pivotal at Craig Hospital

ONWARD Medical reported Q1 2026 results on 26 May 2026 with EUR 2.0 million in revenue (EUR 1.3 million ARC-EX systems across 100+ clinics, 70 systems supplied including first home-use shipments to US VA patients), two additional ARC-BCI participants bringing the total to seven, and first participant enrolled plus first implant in the Empower BP pivotal study at Craig Hospital, Denver. The company holds EUR 53.4 million in cash before adding over EUR 40 million from the April equity raise, extending runway into Q1 2028.

May 27

Market Moves

Inspire Medical cuts 2026 guidance to $825-875M as CMS WISeR consumes the bull case

Inspire Medical Systems reported Q1 2026 revenue of $204.6 million (up 1.6% year-on-year) on 4 May 2026 and cut full-year 2026 guidance to $825-875 million from the prior $950 million-$1 billion range issued in February. The company attributed approximately $20 million of Q1 impact to CMS WISeR prior authorization and CPT code transition uncertainty. Bank of America analyst Travis Steed downgraded the stock from Neutral to Underperform.

May 26

Market Moves

Most of Europe's leading neurotechnology companies trace back to one Geneva research campus

The Friday $7.5 million seed round for Neurosoft Bioelectronics is the latest commercial output from a Lausanne-Geneva neurotechnology cluster anchored on EPFL's Neuro-X Institute at Campus Biotech Geneva. The same cluster has produced ONWARD Medical (now NASDAQ-listed brain-spine interface company), MindMaze (Lausanne-founded brain-technology unicorn), and the academic research that China's brain-spine clinical programmes are now structurally copying.

May 26

Market Moves

Medtronic to acquire SPR Therapeutics for $650 million as top-three neuromodulation incumbents consolidate the peripheral nerve stim category

Medtronic announced on 20 May 2026 its intent to acquire SPR Therapeutics, the maker of the Sprint percutaneous peripheral nerve stimulation system, for approximately $650 million in upfront cash. The deal is the second top-three neuromodulation acquisition of a PNS specialist in seven months, after Boston Scientific completed its $533 million purchase of Nalu Medical in January 2026.

May 21

Market Moves

BlueWind Medical raises $47.8 million to scale Revi as the implantable tibial neuromodulation category separates from sacral nerve stimulation

BlueWind Medical closed $47.8 million in combined equity and debt financing on 14 May 2026 to scale US commercialisation of Revi, the only FDA-cleared implantable tibial neuromodulation device for urgency urinary incontinence. The round follows three-year OASIS pivotal trial data and Medtronic's September 2025 FDA approval of its competing Altaviva tibial system.

May 20

Market Moves

MintNeuro becomes Motif Neurotech's silicon supplier as the BCI supply chain splits from vertical integration

Imperial College London spinout MintNeuro signed a multi-year commercial supply agreement on 6 May 2026 to provide its miniaturised sensing and stimulation integrated circuits to Motif Neurotech's DOT depression implant across pre-clinical, early clinical, and pivotal trial phases. The deal lands two weeks after Motif's FDA Investigational Device Exemption clearance.

May 19